FY2027 EPS Estimates for Amgen Decreased by Erste Group Bank

Amgen Inc. (NASDAQ:AMGN) – Research analysts at Erste Group Bank lowered their FY2027 earnings estimates for shares of Amgen in a research report issued to clients and investors on Friday, September 18th. Erste Group Bank analyst H. Engel now expects that the medical research company will earn $24.36 per share for the year, down from their previous forecast of $24.43. The consensus estimate for Amgen’s current full-year earnings is $22.94 per share.

Other equities research analysts have also recently issued research reports about the company. Bank of America upped their target price on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Scotiabank boosted their price objective on shares of Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 6th. Finally, Mizuho lifted their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $383.46.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $406.09 on Tuesday. The stock has a market capitalization of $219.54 billion, a P/E ratio of 25.24, a P/E/G ratio of 2.96 and a beta of 0.43. The business has a 50-day moving average of $404.47 and a two-hundred day moving average of $368.29. Amgen has a fifty-two week low of $269.77 and a fifty-two week high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS.

Institutional Investors Weigh In On Amgen

Large investors have recently made changes to their positions in the company. Baird Financial Group Inc. boosted its stake in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares in the last quarter. Integrated Advisors Network LLC increased its stake in shares of Amgen by 50.5% in the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after buying an additional 6,356 shares in the last quarter. KBC Group NV raised its holdings in shares of Amgen by 51.7% in the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after buying an additional 130,497 shares during the last quarter. National Pension Service lifted its position in Amgen by 4.7% during the 4th quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock worth $405,717,000 after buying an additional 55,489 shares in the last quarter. Finally, MW Advisory LLC bought a new stake in Amgen during the 2nd quarter worth about $1,054,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase 3 Sjögren’s results strengthen Amgen’s pipeline. Dazodalibep met the primary endpoint in the OASIZ 301 study, producing statistically significant and clinically meaningful improvement in systemic disease activity through week 48. The CD40L antagonist could address a significant unmet need in systemic Sjögren’s disease. Amgen’s autoimmune drug succeeds in late-stage trial
• Positive Sentiment: Some analysts raised or maintained bullish views. Jefferies increased its price target to $410 from $367 following the data, while Goldman Sachs maintained a Buy rating and a $450 target, citing Amgen’s strengthening pipeline and long-term growth prospects. Amgen price target raised by Jefferies to $410 after positive Sjögren’s data
• Neutral Sentiment: Approval timing remains uncertain. Although the trial achieved its main goal, Amgen may need additional trial data before submitting a regulatory filing, limiting how quickly investors can assign commercial value to dazodalibep. Amgen hits primary endpoint in Sjögren’s trial
• Negative Sentiment: Analyst skepticism and valuation are capping enthusiasm. Bank of America maintained an Underperform rating and $317 price target, citing unanswered questions around the data. Amgen also carries substantial leverage, with debt-to-equity of 4.44, and trades at about 25 times earnings, leaving less room for disappointment. Erste Group made a modest reduction to its FY2027 EPS estimate. Amgen Underperform maintained as dazodalibep data uncertainty limits upside

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.